A5103179628- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Urticaria and Related Conditions
- Immune Cell Function and Interaction
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- CAR-T cell therapy research
- Autoimmune and Inflammatory Disorders Research
- Parvovirus B19 Infection Studies
- Otitis Media and Relapsing Polychondritis
- Vasculitis and related conditions
Universitair Ziekenhuis Brussel
2023-2025
Ghent University Hospital
2024-2025
Vrije Universiteit Brussel
2023
KU Leuven
2016-2022
Universitair Ziekenhuis Leuven
2018-2019
We describe two patients in whom malignant monoclonal T-cell lymphoproliferation developed after administration of chimeric antigen receptor (CAR) therapy with ciltacabtagene autoleucel (cilta-cel) the phase 3 CARTITUDE-4 trial. Monoclonal T cells from both had detectable CAR transgene expression and integration. The clinicogenomic features these transgenic lymphoproliferative neoplasms suggest that multiple potential intrinsic or extrinsic factors (or both) contributed to their...
Cytogenetic abnormalities are predictors of poor prognosis in multiple myeloma (MM). This paper aims to build and validate a multiparametric conventional functional whole-body MRI-based prediction model for cytogenetic risk classification newly diagnosed MM.
Multiple myeloma (MM) patients with triple- and penta-refractory disease have a poor survival limited treatment options. Selinexor, in combination bortezomib dexamethasone, demonstrated clinical activity the STOMP study as well BOSTON previously treated refractory to proteasome inhibitor (PI).
Introduction: Impressive therapeutic progress is being made in the management of multiple myeloma (MM). his related to introduction several new classes agents including proteasome inhibitors, immunomodulatory drugs (IMiDs) and monoclonal antibodies (MoAbs).Areas covered: In this manuscript, role IMiDs thalidomide lenalidomide newly diagnosed MM discussed. The mode action their patients highlighted. addition, clinical data on how MoAbs such as anti-CD38 antibody daratumumab can further...
Introduction: Progress in molecular characterization methods has led to major advances the field of hematology and oncology, bringing forth new diagnostic tools therapeutic options. Increased biological knowledge introduction options multiple myeloma (MM), resulting improved progression-free overall survival. However, MM still remains an incurable disease treatment choice is largely empirical, era gradually evolving towards a personalized, patient-tailored approach.Areas covered: This review...
Background: The ubiquitin‐proteasome system (UPS) is crucial for cellular protein homeostasis by ensuring the degradation of redundant or misfolded proteins. In addition to its pleiotropic effects, UPS also plays an important role in different steps erythropoiesis. Proteasome inhibition constitutes one cornerstones current multiple myeloma (MM) treatment, with three proteasome inhibitors (PI) approved clinical use, including reversible bortezomib, ixazomib and irreversible PI carfilzomib....